TABLE 2.
Comparison of GMLVQ analysis of urinary steroid metabolites vs serum assessments using Fib4 and NAFLD fibrosis scores (analysis of samples corrected for urinary creatinine)
| Clinical comparison (NAFLD stage) | AUC ROC (95% confidence intervals) | |||||
|---|---|---|---|---|---|---|
| NAFLD Fibrosis score | FIB‐4 | GMLVQ (32 steroids) | GMLVQ* (32 steroids, age, BMI) | GMLVQ‐10 (top 10 steroid metabolites) | GMLVQ‐10* (top 10 steroid metabolites, age, BMI) | |
| F0‐F2 vs F3‐F4 | 0.87 (0.86‐0.88) | 0.91 (0.89‐0.92) | 0.89 (0.87‐0.90) | 0.92 (0.91‐0.94) | 0.87 (0.85‐0.88) | 0.92 (0.91‐0.94) |
| F0‐F3 vs F4 | 0.87 (0.86‐0.88) | 0.84 (0.83‐0.85) | 0.87 (0.85‐0.89) | 0.92 (0.91‐0.94) | 0.85 (0.83‐0.87) | 0.90 (0.89‐0.92) |
| Controls vs F0‐F4 | 0.93 (0.92‐0.94) | 0.94 (0.92‐0.95) | 0.92 (0.91‐0.93) | 0.94 (0.93‐0.96) | ||
| Controls vs F3‐F4 | 0.99 (0.98‐0.99) | 0.98 (0.97‐0.98) | 0.99 (0.98‐0.99) | 0.98 (0.98‐0.99) | ||
| Controls vs F4 | 1.00 (1.00‐1.00) | 1.00 (1.00‐1.00) | 1.00 (1.00‐1.00) | 1.00 (0.99‐1.00) | ||
Abbreviations: BMI, body mass index; FIB‐4, fibrosis‐4 score; GMLVQ, Generalised Matrix Learning Vector Quantisation; NAFLD, non‐alcoholic fatty liver disease; ROC, receiver operating characteristics.